top of page
iPharmaCenter
News | Blogs | Healthcare | Consulting
Contact:
info@ipharmacenter.com
Home
Pharma
North America
US FDA Approvals
Canada Drug Healthcare News
APAC
China Drug Approvals
India Drug Approvals
APAC - Drug Approvals
Japan Drug Approvals | Healthcare
Europe
EMA News
LACAM
Brazil - Drug approvals
Healthcare News
US Healthcare News
US Payer News
APAC - Healthcare News
Europe Healthcare News
Lacam Healthcare News
Healthcare Policies
Disease News
Immunology
Oncology
Infections_Vaccines
Cardiovascular
Kidney Diseases
Metabolic Diseases
Women Health
Neurology
Conferences
Others
COVID-19
Contact
All Posts
Healthcare Systems
News
Conferences
Know your disease
COVID
Japan drug approvals
USA Pharma News | Healthcare News
Europe Pharma News
Japan drug approvals
Australia Pharma & Healthcare News
Canada Pharma and Healthcare News
Asia | Pharma | Healthcare News
Indication News
Latam
US FDA News
CMS News
India Drug Healthcare
China Drug Approvals
Europe Healthcare News
APAC Drug approvals
US_PayerNews
Australia TGA Approvals
Biosimilars
Radioligand therapy
Chikungunya News
NICE recommendations
G-BA Assessment Outcomes
HAS Assessment Outcomes
Neurology
Immunology
Search
Log in / Sign up
ipharmaservices
Dec 6, 2024
Lilly Takes on Novo Nordisk with Head-to-Head Data Comparing Zepbound and Wegovy | iPharmaCenter
ipharmaservices
Nov 14, 2024
Tirzepatide significantly reduced the risk of progression to type 2 diabetes in adults with prediabetes and obesity, preventing most from developing the disease over 176 weeks | iPharmaCenter
ipharmaservices
Jul 16, 2024
Pfizer decides to continue development of GLP agonist Danuglipron | iPharmaCenter
ipharmaservices
Aug 21, 2023
Obesity News | Overweight | Treatments |Updates | iPharmaCenter
ipharmaservices
Mar 19, 2023
Diabetes mellitus News | iPharmaCenter
ipharmaservices
May 30, 2022
NASH News | Updates | Liver disease
bottom of page